Bactericidal action of daptomycin against stationary-phase and nondividing Staphylococcus aureus cells.
Most antibiotics with bactericidal activity require that the bacteria be actively dividing to produce rapid killing. However, in many infections, such as endocarditis, prosthetic joint infections, and infected embedded catheters, the bacteria divide slowly or not at all. Daptomycin is a lipopeptide antibiotic with a distinct mechanism of action that targets the cytoplasmic membrane of gram-positive organisms, including Staphylococcus aureus. Daptomycin is rapidly bactericidal against exponentially growing bacteria (a 3-log reduction in 60 min). The objectives of this study were to determine if daptomycin is bactericidal against nondividing S. aureus and to quantify the extent of the bactericidal activity. In high-inoculum methicillin-sensitive S. aureus cultures in stationary phase (10(10) CFU/ml), daptomycin displayed concentration-dependent bactericidal activity, requiring 32 micro/ml to achieve a 3-log reduction. In a study comparing several antibiotics at 100 microg/ml, daptomycin demonstrated faster bactericidal activity than nafcillin, ciprofloxacin, gentamicin, and vancomycin. In experiments where bacterial cell growth was halted by the metabolic inhibitor carbonyl cyanide m-chlorophenylhydrazone or erythromycin, daptomycin (10 microg/ml) achieved the bactericidal end point (a 3-log reduction) within 2 h. In contrast, ciprofloxacin (10 microg/ml) did not produce bactericidal activity. Daptomycin (2 microg/ml) remained bactericidal against cold-arrested S. aureus, which was protected from the actions of ciprofloxacin and nafcillin. The data presented here suggest that, in contrast to that of other classes of antibiotics, the bactericidal activity of daptomycin does not require cell division or active metabolism, most likely as a consequence of its direct action on the bacterial membrane.
Mascio
Carmela T M
CT
Cubist Pharmaceuticals, Inc., 65 Hayden Avenue, Lexington, MA 02421,USA. carmela.mascio@cubist.com
Alder
Jeff D
JD
Silverman
Jared A
JA
D000900:Anti-Bacterial Agents / Q000494:pharmacology; D002455:Cell Division / Q000187:drug effects; D002939:Ciprofloxacin / Q000494:pharmacology; D017576:Daptomycin / Q000494:pharmacology*; D004917:Erythromycin / Q000494:pharmacology; D005839:Gentamicins / Q000494:pharmacology; D006835:Hydrazones / Q000494:pharmacology; D008826:Microbial Sensitivity Tests; D009254:Nafcillin / Q000494:pharmacology; D013211:Staphylococcus aureus / Q000187:drug effects* / Q000254:growth & development / Q000378:metabolism; D014640:Vancomycin / Q000494:pharmacology
D000900:Anti-Bacterial Agents; D005839:Gentamicins; D006835:Hydrazones; C070053:carbonyl 3-chlorophenylhydrazone; D009254:Nafcillin; D002939:Ciprofloxacin; D004917:Erythromycin; D014640:Vancomycin; D017576:Daptomycin